Clinical Guidance for Managing Meningococcal Disease Risk in …
Nov 26, 2024 · Receiving complement inhibitor therapy significantly increases a patient's risk for meningococcal disease. Antimicrobial prophylaxis could potentially reduce the risk of …
Therapeutic Targeting of the Complement System: From Rare …
In recent years, a new approach has been developed to block the complement inhibitors in combination with the antitumor antibodies, so-called bispecific antibodies, to increase the …
Complement in human disease: approved and up-and-coming …
Jan 27, 2024 · The finding that eculizumab, a humanised anti-C5 antibody that was approved by the US Food and Drug Administration (FDA) in 2007, can prevent complement-mediated lysis …
Meningococcal Disease and People Receiving Complement Inhibitors
Feb 1, 2024 · People receiving complement inhibitors should seek treatment quickly for symptoms of meningococcal disease. Prompt treatment is important even for those who've been …
Complement Inhibitors: Uses, Dosage, Side Effects ... - RxList
Sep 5, 2023 · Complement inhibitors are a type of immunotherapy used in the treatment of many inflammatory conditions, including lung and multiorgan inflammation caused by COVID-19 …
Advancing therapeutic complement inhibition in hematologic …
Jun 23, 2022 · In this era of several approved targeted complement therapeutics, selection of the proper drug must be based on a personalized approach. Beyond PNH, complement inhibition …
Therapeutic targeting of the complement system - PMC
In some complement-related diseases, the complement response is triggered by one dominant pathway. Specific blockage of one pathway may offer the means of halting detrimental …
Complement inhibition at the level of C3 or C5: mechanistic …
Jan 28, 2021 · Blocking the terminal complement pathway with the C5 inhibitor eculizumab has revolutionized the clinical management of several complement-mediated diseases and has …
Complement Inhibitor Therapy for Myasthenia Gravis - PubMed
Jun 3, 2020 · Second- and third-generation complement inhibitors are in development and approaching pivotal efficacy evaluations. This review will summarize the history and present …
Factor B as a therapeutic target for the treatment of complement ...
Feb 14, 2025 · In this review, we provide an overview of Factor B and its critical role in the AP, discuss the benefit-risk of Factor B inhibition as a targeted therapeutic strategy, and describe …